Bleakley Financial Group LLC Acquires Shares of 37,938 Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Bleakley Financial Group LLC acquired a new stake in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 37,938 shares of the company’s stock, valued at approximately $33,000.

A number of other hedge funds have also added to or reduced their stakes in KPTI. Advisor Group Holdings Inc. increased its position in Karyopharm Therapeutics by 134.3% during the 4th quarter. Advisor Group Holdings Inc. now owns 8,906 shares of the company’s stock valued at $30,000 after purchasing an additional 5,105 shares during the period. Prelude Capital Management LLC purchased a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth about $53,000. Alpine Global Management LLC purchased a new stake in shares of Karyopharm Therapeutics in the 4th quarter worth about $58,000. PEAK6 Investments LLC purchased a new stake in shares of Karyopharm Therapeutics in the 1st quarter worth about $58,000. Finally, State of Wyoming grew its position in shares of Karyopharm Therapeutics by 188.8% in the 4th quarter. State of Wyoming now owns 17,082 shares of the company’s stock worth $58,000 after buying an additional 11,168 shares during the period. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Price Performance

Shares of Karyopharm Therapeutics stock opened at $1.10 on Wednesday. The stock has a market cap of $126.58 million, a price-to-earnings ratio of -0.88 and a beta of 0.03. The firm’s 50-day moving average is $1.35 and its 200 day moving average is $1.05. Karyopharm Therapeutics Inc. has a 1 year low of $0.62 and a 1 year high of $4.87.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The company had revenue of $33.75 million for the quarter, compared to the consensus estimate of $33.50 million. During the same quarter last year, the firm posted ($0.43) EPS. On average, equities analysts expect that Karyopharm Therapeutics Inc. will post -1.19 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reduced their target price on shares of Karyopharm Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, March 1st. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $5.67.

Insider Buying and Selling

In related news, CEO Richard A. Paulson sold 80,470 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $1.17, for a total value of $94,149.90. Following the transaction, the chief executive officer now owns 1,183,783 shares in the company, valued at approximately $1,385,026.11. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Karyopharm Therapeutics news, CEO Richard A. Paulson sold 80,470 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $1.17, for a total transaction of $94,149.90. Following the transaction, the chief executive officer now owns 1,183,783 shares in the company, valued at approximately $1,385,026.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Michael Mason sold 27,687 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $1.17, for a total transaction of $32,393.79. Following the transaction, the chief financial officer now owns 404,918 shares in the company, valued at approximately $473,754.06. The disclosure for this sale can be found here. Insiders have sold a total of 164,542 shares of company stock worth $198,175 in the last quarter. Corporate insiders own 3.32% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).